The pharmacologic inhibition of HDAC2 could serve as a viable therapeutic approach for ESCC patients exhibiting hyperactivation of the METTL14–miR‐99a‐5p–TRIB2 axis. Here, HDAC2 is linked to esophageal squamous cell carcinoma.